News & Updates
Showing Urology articles
Showing

ART discontinuation tied to toxicity, disease progression in mCRPC patients
Several patients with metastatic castration-resistant prostate cancer (mCRPC) discontinue the use of androgen receptor‒targeted therapies (ARTs) because of disease progression, while a few stopped ARTs due to treatment toxicity, according to a study.

Transurethral water vapour thermal therapy effective and safe in Chinese BPH patients
Transurethral water vapour thermal therapy (WVTT) delivered in an office-based setting under local anaesthesia alone is an effective and safe alternative for surgical treatment of benign prostatic hyperplasia (BPH) in Chinese patients, researchers from the Chinese University of Hong Kong (CUHK) have reported.

More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC
Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide reported more fatigue, depression and deterioration in perceived cognitive ability, and slower reaction time than those receiving abiraterone acetate, according to results of the ACE study.

NCHT improves PFS in locally advanced prostate cancer
Neoadjuvant chemohormonal therapy (NCHT) plus radical prostatectomy (RP) confers significant biochemical progression-free survival (bPFS) benefits relative to neoadjuvant hormonal therapy (NHT) plus RP on patients with high-risk, locally advanced prostate cancer, reports a study.





